Wang Li, Liao Bing, Yu Jian, Chen Ling, Cai Xiaozhong, Liu Li, Hou Kaiwen, Zhang Minghao
Lab Teaching and Management Center, Chongqing Medical University, Chongqing 400016, P.R. China.
Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China.
Exp Ther Med. 2020 Feb;19(2):1121-1128. doi: 10.3892/etm.2019.8206. Epub 2019 Dec 6.
The present study aimed to evaluate the utility of the extent of change (C) and change rate (Cr) of cardiac troponin I (cTnI) and hypersensitive C-reactive protein (hs-CRP) prior to and after treatment in evaluating the early therapeutic efficacy of acute myocardial infarction (AMI) treatment. A total of 145 patients with AMI who received regular MI treatment were enrolled in the present study. Patients were divided into the effective group and the ineffective group based on the early therapeutic efficacy. The values of two parameters, namely the serum levels of cTnI and hs-CRP, were collected prior to and after AMI treatment. Data were analyzed by using the t-test, Chi-squared test, logistic regression and receiver operating characteristic (ROC) curve analysis. Compared with those in the ineffective group, the values of cTnI and hs-CRP after treatment [cTnI and hs-CRP], as well as their C and Cr values, were significantly decreased in the effective group (P<0.01). Furthermore, the positive rates (PR) of cTnI, hs-CRP, (cTnI+hs-CRP), C, C and C were significantly lower in the effective group compared with those in the ineffective group (P<0.01). It was indicated that hs-CRP and C, as well as the PR-cTnI and the PR-C, may be used as independent factors for early therapeutic efficacy evaluation (P<0.05). In addition, the area under the ROC curve, as well as the associated sensitivity and specificity analysis for cTnI, hs-CRP, C and Cr, all indicated that these parameters were able to distinguish between the effective and the ineffective groups. The present study revealed that compared with the cTnI and hs-CRP, the C and the Cr of cTnI and hs-CRP may have enhanced value for evaluating the early therapeutic efficacy of AMI treatment.
本研究旨在评估治疗前后心肌肌钙蛋白I（cTnI）和超敏C反应蛋白（hs-CRP）的变化程度（C）和变化率（Cr）在评估急性心肌梗死（AMI）治疗早期疗效中的作用。本研究共纳入145例接受常规心肌梗死治疗的AMI患者。根据早期治疗效果将患者分为有效组和无效组。在AMI治疗前后收集cTnI和hs-CRP这两个参数的血清水平值。采用t检验、卡方检验、逻辑回归和受试者工作特征（ROC）曲线分析进行数据分析。与无效组相比，有效组治疗后的cTnI和hs-CRP值及其C和Cr值均显著降低（P<0.01）。此外，有效组的cTnI、hs-CRP、（cTnI+hs-CRP）、C、C和C的阳性率（PR）显著低于无效组（P<0.01）。结果表明，hs-CRP和C以及PR-cTnI和PR-C可作为早期治疗效果评估的独立因素（P<0.05）。此外，ROC曲线下面积以及对cTnI、hs-CRP、C和Cr的相关敏感性和特异性分析均表明，这些参数能够区分有效组和无效组。本研究表明，与cTnI和hs-CRP相比，cTnI和hs-CRP的C和Cr在评估AMI治疗早期疗效方面可能具有更高的价值。
